Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Y Chang

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
Diabetologia|December 1, 1983
Ciglitazone, a new hypoglycaemic agent. 3. Effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-ob/ob and -+/? miceA Y Chang, B J Gilchrist, B M Wyse
Brain Research|May 21, 1998
Participation of hippocampal formation in negative feedback inhibition of penile erection in the ratA Y Chang, J Y Chan, S H Chan
Optics Letters|September 22, 2009
Simultaneous measurements of velocity, temperature, and pressure using rapid cw wavelength-modulation laser-induced fluorescence of OHA Y Chang, B E Battles, R K Hanson
Hematological Oncology|November 1, 1989
Refractory acute lymphocytic leukemia: response to aclacinomycin A and VP-16-213J M Rowe, A Y Chang, J M Bennett
Journal of Biological Response Modifiers|April 1, 1986
Chemoprevention of 7,12-dimethylbenz(alpha)anthracene (DMBA) induced rat mammary tumors by 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP)A Y Chang, C Chuang, K J Pandya, et al.
American Journal of Clinical Oncology|December 1, 1994
Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancerR K Hsieh, A Y Chang, L Boros, et al.
Cancer Treatment Reports|November 1, 1984
Evaluation of vindesine in patients with refractory small cell lung cancerA Y Chang, R S Witte, D C Tormey, et al.
Journal of Interferon Research|December 1, 1986
Toxicities of human recombinant interferon-alpha 2 in patients with advanced prostate carcinomaA Y Chang, H A Fisher, A S Spiers, et al.
Seminars in Oncology|November 28, 1997
Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancerA Y Chang, L Boros, R Asbury, et al.
Seminars in Oncology|June 1, 1995
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposideL Boros, G C Garrow, R F Asbury, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
Diabetologia|December 1, 1983
Ciglitazone, a new hypoglycaemic agent. 3. Effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-ob/ob and -+/? miceA Y Chang, B J Gilchrist, B M Wyse
Brain Research|May 21, 1998
Participation of hippocampal formation in negative feedback inhibition of penile erection in the ratA Y Chang, J Y Chan, S H Chan
Optics Letters|September 22, 2009
Simultaneous measurements of velocity, temperature, and pressure using rapid cw wavelength-modulation laser-induced fluorescence of OHA Y Chang, B E Battles, R K Hanson
Hematological Oncology|November 1, 1989
Refractory acute lymphocytic leukemia: response to aclacinomycin A and VP-16-213J M Rowe, A Y Chang, J M Bennett
Journal of Biological Response Modifiers|April 1, 1986
Chemoprevention of 7,12-dimethylbenz(alpha)anthracene (DMBA) induced rat mammary tumors by 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP)A Y Chang, C Chuang, K J Pandya, et al.
American Journal of Clinical Oncology|December 1, 1994
Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancerR K Hsieh, A Y Chang, L Boros, et al.
Cancer Treatment Reports|November 1, 1984
Evaluation of vindesine in patients with refractory small cell lung cancerA Y Chang, R S Witte, D C Tormey, et al.
Journal of Interferon Research|December 1, 1986
Toxicities of human recombinant interferon-alpha 2 in patients with advanced prostate carcinomaA Y Chang, H A Fisher, A S Spiers, et al.
Seminars in Oncology|November 28, 1997
Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancerA Y Chang, L Boros, R Asbury, et al.
Seminars in Oncology|June 1, 1995
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposideL Boros, G C Garrow, R F Asbury, et al.
Pageof 13